Lymphomas

Luca Castagna; Massimo Magagnoli; Monica Demarco; Armando Santoro

doi:10.1016/j.uct.2007.08.001

Lymphomas

Luca Castagna, Massimo Magagnoli, Monica Demarco, Armando Santoro

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

Many progresses have been made in the management of non-Hodgkin's lymphoma and Hodgkin's lymphoma. Newer chemotherapeutic regimens, extended use of PET to evaluate the stage and mainly the response after treatment, rituximab and other monoclonal antibodies, radioimmunoconjugates, and allogeneic stem cell transplantation, all contribute to a better treatment of these diseases. Furthermore, risk-adapted treatment can reduce late toxicities, such as cardiovascular disease, secondary myelodysplastic syndrome, and solid tumors.

Original language	English
Pages (from-to)	101-110
Number of pages	10
Journal	Update on Cancer Therapeutics
Volume	2
Issue number	2
DOIs	https://doi.org/10.1016/j.uct.2007.08.001
Publication status	Published - Jun 2007

Keywords

Chemotherapy
Hodgkin's lymphoma
Non-Hodgkin's lymphoma
PET

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1016/j.uct.2007.08.001

Fingerprint Dive into the research topics of 'Lymphomas'. Together they form a unique fingerprint.

Cite this

@article{8649bbea55f349529d4cef3a1d491412,

title = "Lymphomas",

abstract = "Many progresses have been made in the management of non-Hodgkin's lymphoma and Hodgkin's lymphoma. Newer chemotherapeutic regimens, extended use of PET to evaluate the stage and mainly the response after treatment, rituximab and other monoclonal antibodies, radioimmunoconjugates, and allogeneic stem cell transplantation, all contribute to a better treatment of these diseases. Furthermore, risk-adapted treatment can reduce late toxicities, such as cardiovascular disease, secondary myelodysplastic syndrome, and solid tumors.",

keywords = "Chemotherapy, Hodgkin's lymphoma, Non-Hodgkin's lymphoma, PET",

author = "Luca Castagna and Massimo Magagnoli and Monica Demarco and Armando Santoro",

year = "2007",

month = jun,

doi = "10.1016/j.uct.2007.08.001",

language = "English",

volume = "2",

pages = "101--110",

journal = "Update on Cancer Therapeutics",

issn = "1872-115X",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Lymphomas

AU - Castagna, Luca

AU - Magagnoli, Massimo

AU - Demarco, Monica

AU - Santoro, Armando

PY - 2007/6

Y1 - 2007/6

N2 - Many progresses have been made in the management of non-Hodgkin's lymphoma and Hodgkin's lymphoma. Newer chemotherapeutic regimens, extended use of PET to evaluate the stage and mainly the response after treatment, rituximab and other monoclonal antibodies, radioimmunoconjugates, and allogeneic stem cell transplantation, all contribute to a better treatment of these diseases. Furthermore, risk-adapted treatment can reduce late toxicities, such as cardiovascular disease, secondary myelodysplastic syndrome, and solid tumors.

AB - Many progresses have been made in the management of non-Hodgkin's lymphoma and Hodgkin's lymphoma. Newer chemotherapeutic regimens, extended use of PET to evaluate the stage and mainly the response after treatment, rituximab and other monoclonal antibodies, radioimmunoconjugates, and allogeneic stem cell transplantation, all contribute to a better treatment of these diseases. Furthermore, risk-adapted treatment can reduce late toxicities, such as cardiovascular disease, secondary myelodysplastic syndrome, and solid tumors.

KW - Chemotherapy

KW - Hodgkin's lymphoma

KW - Non-Hodgkin's lymphoma

KW - PET

UR - http://www.scopus.com/inward/record.url?scp=34548590459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548590459&partnerID=8YFLogxK

U2 - 10.1016/j.uct.2007.08.001

DO - 10.1016/j.uct.2007.08.001

M3 - Article

AN - SCOPUS:34548590459

VL - 2

SP - 101

EP - 110

JO - Update on Cancer Therapeutics

JF - Update on Cancer Therapeutics

SN - 1872-115X

IS - 2

ER -